Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Real Time Quote from BATS)

$43.08 USD

43.08
140,337

-1.20 (-2.71%)

Updated Apr 25, 2024 12:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RARE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 577 748 740 1,202 755
Receivables 73 40 28 23 33
Notes Receivable 0 0 0 0 0
Inventories 34 27 16 13 12
Other Current Assets 48 69 72 58 51
Total Current Assets 732 884 857 1,295 851
Net Property & Equipment 291 260 141 74 44
Investments & Advances 200 155 294 166 33
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 211 205 175 176 173
Deposits & Other Assets 58 17 21 9 3
Total Assets 1,491 1,545 1,522 1,760 1,136
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 42 43 17 13 13
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 196 205 146 108 83
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 29 1 8 59 0
Total Current Liabilities 280 261 181 190 103
Mortgages 0 0 0 0 0
Deferred Taxes/Income 30 32 33 33 33
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 875 880 354 343 315
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,216 1,193 600 605 482
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 3,662 3,140 2,998 2,773 2,087
Retained Earnings -3,388 -2,781 -2,074 -1,620 -1,433
Other Equity 1 -7 -1 1 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 275 352 923 1,154 654
Total Liabilities & Shareholder's Equity 1,491 1,545 1,522 1,760 1,136
Total Common Equity 275 352 923 1,154 654
Shares Outstanding 82.10 70.10 68.10 61.00 57.70
Book Value Per Share 3.35 5.03 13.55 18.92 11.33

Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 577 442 552 629
Receivables NA 73 79 71 43
Notes Receivable NA 0 0 0 0
Inventories NA 34 32 28 27
Other Current Assets NA 48 46 51 67
Total Current Assets NA 732 599 702 766
Net Property & Equipment NA 291 297 289 278
Investments & Advances NA 200 86 72 90
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 211 202 203 204
Deposits & Other Assets NA 58 28 26 22
Total Assets NA 1,491 1,238 1,311 1,383
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 42 33 42 59
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 196 179 168 144
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 29 30 24 4
Total Current Liabilities NA 280 254 244 218
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 30 32 32 32
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 886 891 896
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,216 1,206 1,182 1,163
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 3,662 3,298 3,237 3,169
Retained Earnings NA -3,388 -3,264 -3,105 -2,945
Other Equity NA 1 -2 -3 -4
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 275 32 129 220
Total Liabilities & Shareholder's Equity NA 1,491 1,238 1,311 1,383
Total Common Equity 0 275 32 129 220
Shares Outstanding 82.30 82.10 82.10 70.80 70.60
Book Value Per Share 0.00 3.35 0.39 1.82 3.12